文献速递慢性肾脏病

核磷酸酶SCP4通过调控FoxO转录因子促进慢性肾脏病肌肉消耗

The nuclear phosphatase SCP4 regulates FoxO transcription factors during muscle wasting in chronic kidney disease.
PubMed 文献 · Kidney Int · 2017-05-12

本研究探讨核磷酸酶SCP4在慢性肾脏病(CKD)肌肉消耗中的作用。在培养小鼠成肌细胞中,SCP4过表达刺激蛋白水解,敲低则阻止炎性细胞因子诱导的蛋白水解;SCP4过表达促进FoxO1/3a核积聚并增加myostatin、Atrogin-1和MuRF-1表达。CKD小鼠和患者骨骼肌中SCP4表达上调,敲低SCP4可抑制FoxO1/3a介导的Atrogin-1和MuRF-1表达并防止CKD小鼠肌肉消耗。

要点

  • SCP4通过促进FoxO1/3a核积聚上调Atrogin-1和MuRF-1,驱动蛋白水解。
  • CKD小鼠和患者骨骼肌中SCP4表达显著增加。
  • 敲低SCP4可防止CKD小鼠肌肉消耗,提示其作为治疗靶点。

核心结论

  • SCP4是FoxO转录因子的新型调节因子,促进细胞蛋白水解,靶向SCP4可能预防CKD及其他分解代谢状况下的肌肉消耗。

研究设计与样本

  • 研究采用培养小鼠成肌细胞(C2C12肌管)和小鼠CKD模型,并检测CKD患者骨骼肌样本。

主要发现

  • 在培养小鼠成肌细胞中,SCP4过表达刺激蛋白水解,而敲低SCP4阻止炎性细胞因子刺激的蛋白水解。
  • SCP4过表达导致FoxO1/3a核积聚,并增加myostatin、Atrogin-1和MuRF-1表达及诱导溶酶体介导的蛋白水解。
  • 促炎细胞因子以NF-κB依赖方式刺激C2C12肌管中SCP4表达。
  • CKD小鼠和患者骨骼肌中SCP4表达上调;敲低SCP4抑制FoxO1/3a介导的Atrogin-1和MuRF-1表达并防止CKD小鼠肌肉消耗。

临床怎么用

  • SCP4可能作为CKD肌肉消耗的潜在治疗靶点,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) and related inflammatory responses stimulate protein-energy wasting, a complication causing loss of muscle mass. Primarily, muscle wasting results from accelerated protein degradation via autophagic/lysosomal and proteasomal pathways, but mechanisms regulating these proteolysis pathways remain unclear. Since dephosphorylation of FoxOs regulates ubiquitin/proteasome protein metabolism, we tested whether a novel nuclear phosphatase, the small C-terminal domain phosphatase (SCP) 4, regulates FoxOs signaling and, in turn, muscle wasting. In cultured mouse myoblast cells, SCP4 overexpression stimulated proteolysis, while knockdown of SCP4 prevented the proteolysis stimulated by inflammatory cytokines. SCP4 overexpression led to nuclear accumulation of FoxO1/3a followed by increased expression of catabolic factors including myostatin, Atrogin-1, and MuRF-1, and induction of lysosomal-mediated proteolysis. Treatment of C2C12 myotubes with proinflammatory cytokines stimulated SCP4 expression in an NF-κB-dependent manner. In skeletal muscle of mice with CKD, SCP4 expression was up-regulated. Similarly, in skeletal muscle of patients with CKD, SCP4 expression was significantly increased. Knockdown of SCP4 significantly suppressed FoxO1/3a-mediated expression of Atrogin-1 and MuRF-1 and prevented muscle wasting in mice with CKD. Thus, SCP4 is a novel regulator of FoxO transcription factors and promotes cellular proteolysis. Hence, targeting SCP4 may prevent muscle wasting in CKD and possibly other catabolic conditions.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Liu X, Yu R, Sun L, et al. The nuclear phosphatase SCP4 regulates FoxO transcription factors during muscle wasting in chronic kidney disease. Kidney Int. 2017. PMID: 28506762. doi:10.1016/j.kint.2017.02.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。